Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Rapport Therapeutics Inc (NASDAQ: RAPP) closed at $25.66 in the last session, up 1.18% from day before closing price of $25.36. In other words, the price has increased by $1.18 from its previous closing price. On the day, 0.55 million shares were traded. RAPP stock price reached its highest trading level at $26.46 during the session, while it also had its lowest trading level at $24.17.
Ratios:
We take a closer look at RAPP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 36.37 and its Current Ratio is at 36.37. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on September 16, 2025, initiated with a Buy rating and assigned the stock a target price of $44.
On August 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $31.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 15 ’25 when Bredt David sold 8,500 shares for $25.79 per share. The transaction valued at 219,196 led to the insider holds 409,642 shares of the business.
Ceesay Abraham sold 5,833 shares of RAPP for $150,541 on Oct 15 ’25. The Chief Executive Officer now owns 579,579 shares after completing the transaction at $25.81 per share. On Oct 15 ’25, another insider, Ceesay Abraham, who serves as the Chief Executive Officer of the company, sold 5,083 shares for $25.81 each. As a result, the insider received 131,189 and left with 41,061 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RAPP now has a Market Capitalization of 1222984704 and an Enterprise Value of 721830784.
Stock Price History:
The Beta on a monthly basis for RAPP is 1.88, which has changed by -0.046096683 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, RAPP has reached a high of $42.27, while it has fallen to a 52-week low of $6.43. The 50-Day Moving Average of the stock is 0.70%, while the 200-Day Moving Average is calculated to be 64.83%.
Shares Statistics:
According to the various share statistics, RAPP traded on average about 782.89K shares per day over the past 3-months and 417030 shares per day over the past 10 days. A total of 47.65M shares are outstanding, with a floating share count of 28.86M. Insiders hold about 39.45% of the company’s shares, while institutions hold 48.52% stake in the company. Shares short for RAPP as of 1760486400 were 2016786 with a Short Ratio of 2.58, compared to 1757894400 on 3158524. Therefore, it implies a Short% of Shares Outstanding of 2016786 and a Short% of Float of 8.180001.
Earnings Estimates
A comprehensive evaluation of Rapport Therapeutics Inc (RAPP) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.84, with high estimates of -$0.7 and low estimates of -$1.14.
Analysts are recommending an EPS of between -$2.72 and -$2.95 for the fiscal current year, implying an average EPS of -$2.84. EPS for the following year is -$3.82, with 5.0 analysts recommending between -$3.3 and -$4.45.
